Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
TGF-β receptor maintains CD4 T helper cell identity during chronic viral infections
Gavin M. Lewis, … , Hendrik Streeck, Elina I. Zuniga
Gavin M. Lewis, … , Hendrik Streeck, Elina I. Zuniga
Published September 6, 2016
Citation Information: J Clin Invest. 2016;126(10):3799-3813. https://doi.org/10.1172/JCI87041.
View: Text | PDF
Research Article Immunology

TGF-β receptor maintains CD4 T helper cell identity during chronic viral infections

  • Text
  • PDF
Abstract

Suppression of CD8 and CD4 T cells is a hallmark in chronic viral infections, including hepatitis C and HIV. While multiple pathways are known to inhibit CD8 T cells, the host molecules that restrict CD4 T cell responses are less understood. Here, we used inducible and CD4 T cell–specific deletion of the gene encoding the TGF-β receptor during chronic lymphocytic choriomeningitis virus infection in mice, and determined that TGF-β signaling restricted proliferation and terminal differentiation of antiviral CD4 T cells. TGF-β signaling also inhibited a cytotoxic program that includes granzymes and perforin expression at both early and late stages of infection in vivo and repressed the transcription factor eomesodermin. Overexpression of eomesodermin was sufficient to recapitulate in great part the phenotype of TGF-β receptor–deficient CD4 T cells, while SMAD4 was necessary for CD4 T cell accumulation and differentiation. TGF-β signaling also restricted accumulation and differentiation of CD4 T cells and reduced the expression of cytotoxic molecules in mice and humans infected with other persistent viruses. These data uncovered an eomesodermin-driven CD4 T cell program that is continuously suppressed by TGF-β signaling. During chronic viral infection, this program limits CD4 T cell responses while maintaining CD4 T helper cell identity.

Authors

Gavin M. Lewis, Ellen J. Wehrens, Lara Labarta-Bajo, Hendrik Streeck, Elina I. Zuniga

×

Figure 6

Exclusive ablation of TGFβ-RII in CD4 T cells enhanced their numbers and terminal differentiation but limited LCMV-specific IgG1 during chronic infection.

Options: View larger image (or click on image) Download as PowerPoint
Exclusive ablation of TGFβ-RII in CD4 T cells enhanced their numbers and...
(A) Cd4-ERCre+ Tgfbr2fl/fl (iCD4-RIIflox, red) mice, Cd4-ERCre+ Tgfbr2fl/+ heterozygotes (HET, gray) and Cre– littermate controls (WT, black) were infected with 2 × 106 PFU of LCMV Cl13. Blood was monitored by flow cytometry prior to infection (A and B) and at the indicated time points after infection (C–G). (A) TGFβ-RII expression over isotype (filled histogram) on B cells and CD4 and CD8 T cells prior to infection. Mean fluorescence intensity (MFI) for TGFβ-RII on CD4 T cells is graphed. (B) Percentage of activated CD44+CD62L– CD4 T cells prior to infection. (C) Percentage and number of virus-specific PD1+CD49d+ cells over time after infection. (D) Percentage and number of PSGL1+Ly6C+ cells within activated CD4 T cells from C. (E) Percentage and number of EOMES- and granzyme B–expressing cells within activated CD4 T cells from C. (F) Expression overlay of indicated marker in EOMES+ (black line) vs. EOMES– (gray fill) activated TGFβ-RII–deficient CD4 T cells from C. (G) Anti-LCMV (αLCMV) Ig levels in serum at postinfection day 30. (H) Viremia by plaque assay, as pooled results from 2 experiments. Representative of 3 independent experiments, with n = 4 or 5 mice/group. Two-way ANOVA (A–H), paired t test (F), *P < 0.05, **P < 0.005, ***P < 0.0005.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts